Skip to main content

Grafa News and Videos — Page 1635

Latest

Grafa

CollPlant narrowed net loss in 2025 as AbbVie milestone drives revenue surge

CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetic medicine company developing innovative technologies based on its proprietary plant-derived recombinant human collagen (rhCollagen), today reported financial results for the full year ended December 31, 2025.

Read more: CollPlant narrowed net loss in 2025 as AbbVie milestone drives revenue surge
Grafa

MetaVia reports 9.1% weight loss in Phase 1 trial as clinical pipeline advances

MetaVia (NASDAQ:MTVA), a clinical-stage biopharmaceutical company developing novel therapies for obesity and metabolic-associated steatohepatitis (MASH), today reported financial results for the full year ended December 31, 2025, and provided an update on its advancing clinical pipeline.

Read more: MetaVia reports 9.1% weight loss in Phase 1 trial as clinical pipeline advances
Grafa

Aptevo Therapeutics reports 86% clinical benefit rate for Mipletamig in frontline AML

Aptevo Therapeutics (NASDAQ:APVO), a clinical-stage biopharmaceutical company focused on developing novel bispecific and multispecific immunotherapies for cancer, today reported financial results for the year ended December 31, 2025, and provided a strategic business update.

Read more: Aptevo Therapeutics reports 86% clinical benefit rate for Mipletamig in frontline AML
Grafa

Cognition Therapeutics aligns with FDA on registrational path for lewy body dementia treatment

Cognition Therapeutics (NASDAQ:CGTX), a clinical-stage biopharmaceutical company developing next-generation therapies for neurodegenerative disorders, today reported financial results for the full year ended December 31, 2025, and provided a comprehensive update on its lead candidate, zervimesine (CT1812).

Read more: Cognition Therapeutics aligns with FDA on registrational path for lewy body dementia treatment
Grafa

MapLight Therapeutics surpasses $450M cash position as key clinical readouts approach

MapLight Therapeutics (NASDAQ:MPLT), a biopharmaceutical company focused on circuit-specific therapies for central nervous system (CNS) disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025.

Read more: MapLight Therapeutics surpasses $450M cash position as key clinical readouts approach
Grafa

Acumen Pharmaceuticals secures $35M for brain-delivery platform as Alzheimer’s trial reaches key milestone

Acumen Pharmaceuticals (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel targeted immunotherapy for Alzheimer’s disease, today reported financial results for the full year ended December 31, 2025, and provided a comprehensive business update.

Read more: Acumen Pharmaceuticals secures $35M for brain-delivery platform as Alzheimer’s trial reaches key milestone

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift